Furqan Shaikh

Furqan Shaikh

Auto-generated profile, based on publicly available information

Furqan Shaikh

Division of Hematology and Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2013 in BMJ
Verified
Journal Article
Open access
PDF file
FSFurqan Shaikh
Furqan Shaikh
JBJack Brzezinski
Jack Brzezinski
SASarah Alexander
Sarah Alexander
CACristian Arzola
Cristian Arzola
JCJ. C. A. Carvalho
J. C. A. Carvalho
LSLillian Sung
Lillian Sung
Objective To determine whether ultrasound imaging can reduce the risk of failed lumbar punctures or epidural catheterisations, when compared with standard palpation methods, and whether ultrasound imaging can reduce traumatic procedures, insertion attempts, and needle redirections. Design Systematic review and meta-analysis of randomised controlled trials. Data sources Ovid Medline, Embase, and Cochrane Central Register of Controlled Trials up to May 2012, without restriction by language or publication status. Review methods Randomised trials that compared ultrasound imaging with standard methods (no imaging) in the performance of a lumbar puncture or epidural catheterisation were identified. Results 14 studies with a total of 1334 patients were included (674 patients assigned to the ultrasound group, 660 to the control group). Five studies evaluated lumbar punctures and nine evaluated epidural catheterisations. Six of 624 procedures conducted in the ultrasound group failed; 44 of 610 procedures in the control group failed. Ultrasound imaging reduced the risk of failed procedures (risk ratio 0.21 (95% confidence interval 0.10 to 0.43), P<0.001). Risk reduction was similar when subgroup analysis was performed for lumbar punctures (risk ratio 0.19 (0.07 to 0.56), P=0.002) or epidural catheterisations (0.23 (0.09 to 0.60), P=0.003). Ultrasound imaging also significantly reduced the risk of traumatic procedures (risk ratio 0.27 (0.11 to 0.67), P=0.005), the number of insertion attempts (mean difference −0.44 (−0.64 to −0.24), P<0.001), and the number of needle redirections (mean difference −1.00 (−1.24 to −0.75), P<0.001). Conclusions Ultrasound imaging can reduce the risk of failed or traumatic lumbar punctures and epidural catheterisations, as well as the number of needle insertions and redirections. Ultrasound may be a useful adjunct for these procedures.

23 November 2015 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
FSFurqan Shaikh
Furqan Shaikh
LDL. Lee Dupuis
L. Lee Dupuis
SASarah Alexander
Sarah Alexander
AGAbha Gupta
Abha Gupta
LMLuc Mertens
Luc Mertens
Paul NathanPaul Nathan
Paul Nathan
Background: Several randomized controlled trials (RCTs) have demonstrated that dexrazoxane reduces anthracycline cardiotoxicity in adults, but use in children has been hindered by lack of direct evidence of cardioprotection and concerns regarding second malignant neoplasms (SMNs). This study aimed to systematically review the evidence regarding dexrazoxane in children. Methods: We searched Medline, Embase, the Cochrane Library, and abstracts for RCTs and nonrandomized studies (NRSs) that compared dexrazoxane to no cardioprotection among children. We combined findings using random-effects models. All statistical tests were two-sided. Results: Eleven eligible publications reported results from five RCTs (1254 patients), and 15 publications reported results from 12 NRSs (3385 patients). Dexrazoxane did not impact clinical cardiotoxicity in RCTs because of a low cardiotoxic event rate (three events among all patients) but was associated with a reduction in subclinical cardiotoxicity. Among NRSs, dexrazoxane was associated with a reduction in clinical cardiotoxicity (relative risk (RR) = 0.29, P = .001) and clinical+subclinical cardiotoxicity (RR = 0.43, P < .001). Among RCTs, 17 of 635 (2.7%) patients treated with dexrazoxane developed an SMN compared with seven of 619 (1.1%) who did not receive dexrazoxane (RR = 2.37, P = .06). Two RCTs that used concurrent etoposide reported an increased risk of acute myeloid leukemia, while one that used cranial radiation reported an increased risk of brain tumors. Event-free survival did not differ (P = .91). Conclusion: Dexrazoxane is associated with a statistically significant risk reduction for most cardiotoxic outcomes. Dexrazoxane is associated with a statistically borderline increase in SMNs, possibly because of an interaction with concurrent cancer therapies. The decision to use dexrazoxane in children should balance the risks of cardiotoxicity and SMNs specific to each treatment protocol.

1 April 2016 in The Lancet Oncology
Verified
Journal Article
Open access
FSFurqan Shaikh
Furqan Shaikh
MMMatthew J Murray
Matthew J Murray
JAJames F Amatruda
James F Amatruda
NCNicholas Coleman
Nicholas Coleman
JNJames C Nicholson
James C Nicholson
AFA Lindsay Frazier
A Lindsay Frazier
Management of paediatric extracranial germ-cell tumours carries a unique set of challenges. Germ-cell tumours are a heterogeneous group of neoplasms that present across a wide age range and vary in site, histology, and clinical behaviour. Patients with germ-cell tumours are managed by a diverse array of specialists. Thus, staging, risk stratification, and treatment approaches for germ-cell tumours have evolved disparately along several trajectories. Paediatric germ-cell tumours differ from the adolescent and adult disease in many ways, leading to complexities in applying age-appropriate, evidence-based care. Suboptimal outcomes remain for several groups of patients, including adolescents, and patients with extragonadal tumours, high tumour markers at diagnosis, or platinum-resistant disease. Survivors have significant long-term toxicities. The challenge moving forward will be to translate new insights from molecular studies and collaborative clinical data into improved patient outcomes. Future trials will be characterised by improved risk-stratification systems, biomarkers for response and toxic effects, rational reduction of therapy for low-risk patients and novel approaches for poor-risk patients, and improved international collaboration across paediatric and adult cooperative research groups.

1 May 2014 in European Journal of Cancer
Verified
Journal Article
Closed access
FSFurqan Shaikh
Furqan Shaikh
LVLaura Voicu
Laura Voicu
STSoumitra Tole
Soumitra Tole
TTTeresa To
Teresa To
ADAndrea S. Doria
Andrea S. Doria
SASarah Alexander
Sarah Alexander

15 June 2012 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
FSFurqan Shaikh
Furqan Shaikh
BNBo‐Yee Ngan
Bo‐Yee Ngan
SASarah Alexander
Sarah Alexander
RGRonald Grant
Ronald Grant

10 April 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
FSFurqan Shaikh
Furqan Shaikh
JCJohn W. Cullen
John W. Cullen
TOThomas A. Olson
Thomas A. Olson
FPFarzana Pashankar
Farzana Pashankar
MMMarcio H. Malogolowkin
Marcio H. Malogolowkin
AFA. Lindsay Frazier
A. Lindsay Frazier
Purpose: To investigate whether event-free survival (EFS) can be maintained among children and adolescents with intermediate-risk (IR) malignant germ cell tumors (MGCT) if the administration of cisplatin, etoposide, and bleomycin (PEb) is reduced from four to three cycles and compressed from 5 to 3 days per cycle. Patients and Methods: In a phase 3, single-arm trial, patients with IR MGCT (stage II-IV testicular, II-III ovarian, I-II extragonadal, or stage I gonadal tumors with subsequent recurrence) received three cycles of PEb. A parametric comparator model specified that the observed EFS rate should not be significantly < 92%. As recommended for trials that test a reduction of therapy, a one-sided P value ≤ .10 was used to indicate statistical significance. In a post hoc analysis, we also compared results to the EFS rate of comparable patients treated with four cycles of PEb in two prior studies. Results: Among 210 eligible patients enrolled from 2003 to 2011, 4-year EFS (EFS4) rate was 89% (95% confidence interval, 83% to 92%), which was significantly lower than the 92% threshold of the comparison model ( P = .08). Among 181 newly diagnosed patients, the EFS4 rate was 87%, compared with 92% for 92 comparable children in the historical cohort ( P = .15). The EFS4 rate was significantly associated with stage (stage I, 100%; stage II, 92%; stage III, 85%; and stage IV, 54%; P < .001). Conclusion: The EFS rate for children with IR MGCT observed after three cycles of PEb was less than that of a prespecified parametric model, particularly for patients with higher-stage tumors. These data do not support a reduction in the number of cycles of PEb from four to three. However, further investigation of a reduction in the number of cycles for patients with lower-stage tumors is warranted.